Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration

Experimental Neurology

Volumn 228, Issue 1, 2011, Pages 118-125

  Baydyuk, Maryna ^a   Nguyen, Madeline T ^a   Xu, Baoji ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopaminergic neurons; MPTP; Neuronal survival; Reactive gliosis; Substantia nigra pars compacta; TrkB; Ventral tegmental area

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GLIOSIS; HYPERSENSITIVITY; MOUSE; NERVE ENDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

ANIMALS; CORPUS STRIATUM; DOPAMINE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; NERVE DEGENERATION; PARKINSON DISEASE; RANDOM ALLOCATION; RECEPTOR, TRKB; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 79851511400     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.12.018     Document Type: Article

References (43)

1. An J.J., Gharami K., Liao G.Y., Woo N.H., Lau A.G., Vanevski F., Torre E.R., Jones K.R., Feng Y., Lu B., Xu B. Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 2008, 134:175-187.
2. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci. 2005, 25:6251-6259.
3. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299:256-259.
4. Conner J.M., Lauterborn J.C., Yan Q., Gall C.M., Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J. Neurosci. 1997, 17:2295-2313.
5. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
6. Dymecki J., Lechowicz W., Bertrand E., Szpak G.M. Changes in dopaminergic neurons of the mesocorticolimbic system in Parkinson's disease. Folia Neuropathol. 1996, 34:102-106.
7. Forno L.S., DeLanney L.E., Irwin I., Di Monte D., Langston J.W. Astrocytes and Parkinson's disease. Prog. Brain Res. 1992, 94:429-436.
8. Gharami K., Xie Y., An J.J., Tonegawa S., Xu B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 2008, 105:369-379.
9. Gorski J.A., Zeiler S.R., Tamowski S., Jones K.R. Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J. Neurosci. 2003, 23:6856-6865.
10. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., Hirsch E.C. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl Acad. Sci. USA 2000, 97:2875-2880.
11. Hartmann A., Hunot S., Hirsch E.C. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Exp. Neurol. 2003, 184:561-564.
12. Hirsch E.C., Hunot S., Damier P., Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann. Neurol. 1998, 44:S115-S120.
13. Howells D.W., Porritt M.J., Wong J.Y., Batchelor P.E., Kalnins R., Hughes A.J., Donnan G.A. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 2000, 166:127-135.
14. Hu C.J., Sung S.M., Liu H., Chang J.G. No mutation of G209A in the alpha-synuclein gene in sporadic Parkinson's disease among Taiwan Chinese. Eur. Neurol. 1999, 41:85-87.
15. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
16. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
17. Kim R.H., Smith P.D., Aleyasin H., Hayley S., Mount M.P., Pownall S., Wakeham A., You-Ten A.J., Kalia S.K., Horne P., Westaway D., Lozano A.M., Anisman H., Park D.S., Mak T.W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA 2005, 102:5215-5220.
18. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
19. Kramer E.R., Aron L., Ramakers G.M., Seitz S., Zhuang X., Beyer K., Smidt M.P., Klein R. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 2007, 5:e39.
20. Krieglstein K. Factors promoting survival of mesencephalic dopaminergic neurons. Cell Tissue Res. 2004, 318:73-80.
21. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
22. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395:451-452.
23. Levivier M., Przedborski S., Bencsics C., Kang U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 1995, 15:7810-7820.
24. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., Nagatsu T. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci. Lett. 1999, 270:45-48.
25. Muthane U., Ramsay K.A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., Ferreira M., Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp. Neurol. 1994, 126:195-204.
26. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., de Munain A.L., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
27. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport 1999, 10:557-561.
28. Payami H., Zareparsi S. Genetic epidemiology of Parkinson's disease. J. Geriatr. Psychiatry Neurol. 1998, 11:98-106.
29. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
30. Przedborski S., Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. NY Acad. Sci. 2003, 991:189-198.
31. Scott W.K., Yamaoka L.H., Stajich J.M., Scott B.L., Vance J.M., Roses A.D., Pericak-Vance M.A., Watts R.L., Nance M., Hubble J., Koller W., Stern M.B., Colcher A., Allen F.H., Hiner B.C., Jankovic J., Ondo W., Laing N.G., Mastaglia F., Goetz C., Pappert E., Small G.W., Masterman D., Haines J.L., Davies T.L. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics 1999, 2:191-192.
32. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 1990, 527:7-20.
33. Shults C.W., Kimber T., Altar C.A. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. NeuroReport 1995, 6:1109-1112.
34. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
35. Tatton N.A., Maclean-Fraser A., Tatton W.G., Perl D.P., Olanow C.W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann. Neurol. 1998, 44:S142-S148.
36. Tsukahara T., Takeda M., Shimohama S., Ohara O., Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 1995, 37:733-739. discussion 739-741.
37. Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4:365-375.
38. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 1993, 14:275-285.
39. Xu B., Gottschalk W., Chow A., Wilson R.I., Schnell E., Zang K., Wang D., Nicoll R.A., Lu B., Reichardt L.F. The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. J. Neurosci. 2000, 20:6888-6897.
40. Xu B., Zang K., Ruff N.L., Zhang Y.A., McConnell S.K., Stryker M.P., Reichardt L.F. Cortical degeneration in the absence of neurotrophin signaling: dendritic retraction and neuronal loss after removal of the receptor TrkB. Neuron 2000, 26:233-245.
41. Yan Q., Radeke M.J., Matheson C.R., Talvenheimo J., Welcher A.A., Feinstein S.C. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J. Comp. Neurol. 1997, 378:135-157.
42. Zaman V., Nelson M.E., Gerhardt G.A., Rohrer B. Neurodegenerative alterations in the nigrostriatal system of trkB hypomorphic mice. Exp. Neurol. 2004, 190:337-346.
43. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.